Niels Marcussen

Prof. Niels Marcussen

Pathology, Hospital Sønderjylland, Aabenraa, Denmark
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2010 in British Journal of Cancer
Verified
Journal Article
Open access
AJA N Jeppesen
A N Jeppesen
HJH K Jensen
H K Jensen
FDF Donskov
F Donskov
NMNiels Marcussen
Niels Marcussen
HMH von der Maase
H von der Maase
Background: Methods: Results: Conclusion:

9 February 2016 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
MAMohamed Abdelgawad
Mohamed Abdelgawad
Jean-Marie DelaisseJean-Marie Delaisse
Jean-Marie Delaisse
MHMaja Hinge
Maja Hinge
PJPia Rosgaard Jensen
Pia Rosgaard Jensen
RARagad Walid Alnaimi
Ragad Walid Alnaimi
TAThomas Levin Andersen
Thomas Levin Andersen

22 July 2020 in ACR Open Rheumatology
Verified
Journal Article
Open access
PDF file
Amir EmamifarAmir Emamifar
Amir Emamifar
TPTorkell Ellingsen Professor
Torkell Ellingsen Professor
Søren HessSøren Hess
Søren Hess
Oke GerkeOke Gerke
Oke Gerke
RLRasmus Hviid Larsen
Rasmus Hviid Larsen
PTPeter Thye‐Rønn
Peter Thye‐Rønn
Objective: To define the proportions of agreement between fluorine‐18‐fluorodeoxyglucose (18F‐FDG) positron emission tomography/computed tomography (PET/CT), clinical diagnosis, and temporal artery biopsy (TAB) in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Furthermore, the association of 18F‐FDG PET/CT uptake patterns and clinical presentation of newly diagnosed PMR and GCA was investigated.Methods: Eighty patients newly suspected of having PMR, GCA, or concomitant PMR and GCA were included and followed for 40 weeks. Every patient underwent an 18F‐FDG PET/CT scan before or within 3 days of initiation of steroids in case of GCA. FDG uptakes in 8 paired articular/periarticular sites and 14 arterial segments were evaluated based on a 4‐point visual grading scale.Results: Of the 80 patients (female: 50 [62.5%]; mean age ± SD: 72.0 ± 7.9), 64 (80.0%) patients were diagnosed with pure PMR, 3 (3.7%) with pure GCA, and 10 (12.5%) with concomitant PMR and GCA. Additionally, three (3.7%) patients were diagnosed with seronegative rheumatoid arthritis during the follow‐up period. For the diagnosis of PMR, 18F‐FDG PET/CT had a proportion of agreement of 75.3 (64.2‐84.4), compared with clinical diagnosis. When comparing findings of 18F‐FDG PET/CT with TAB, 18F‐FDG PET/CT had a proportion of agreement of 93.0 (84.3‐97.7) in all included patients and 69.2 (38.6‐90.9) in the subgroup of patients with vasculitis. C‐reactive protein was significantly higher in patients with PMR activity on 18F‐FDG PET/CT compared with those without 18F‐FDG PET/CT activity (P value = 0.006).Conclusions: 18F‐FDG PET/CT is a powerful imaging technique in PMR and GCA that was in good agreement with clinical diagnosis and TAB.

1 January 2015 in Cancer Letters
Verified
Journal Article
Closed access
Barbara GuerraBarbara Guerra
Barbara Guerra
TRTine D.L. Rasmussen
Tine D.L. Rasmussen
ASAlexander Schnitzler
Alexander Schnitzler
HJHans H. Jensen
Hans H. Jensen
BBBrigitte S. Boldyreff
Brigitte S. Boldyreff
Olaf-Georg IssingerOlaf-Georg Issinger
Olaf-Georg Issinger

27 February 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
LMLine A. Mortensen
Line A. Mortensen
BJBente Jespersen
Bente Jespersen
AHAnne Sophie L. Helligsoe
Anne Sophie L. Helligsoe
BTBirgitte Tougaard
Birgitte Tougaard
DCDonata Cibulskyte-Ninkovic
Donata Cibulskyte-Ninkovic
HTHelle C. Thiesson
Helle C. Thiesson
Key Points: Spironolactone is safe for kidney transplant patients. Spironolactone reduces kidney function by an acute effect, whereafter it remains stable. Spironolactone does not affect the progression of interstitial fibrosis in protocol biopsies. Background: Long-term kidney allograft survival is hampered by progressive interstitial fibrosis and tubular atrophy. The SPIREN trial tested the hypothesis that the mineralocorticoid receptor antagonist spironolactone stabilizes kidney function and attenuates glomerular barrier injury in kidney transplant patients treated with calcineurin inhibitors. Methods: We conducted a randomized, placebo-controlled, double-blind clinical trial including 188 prevalent kidney transplant patients. Patients were randomized to spironolactone or placebo for 3 years. GFR was measured along with proteinuria and kidney fibrosis. The primary end point was change in measured GFR. Secondary outcomes were 24-hour proteinuria, kidney allograft fibrosis, and cardiovascular events. Measured GFRs, 24-hour proteinuria, and BP were determined yearly. Kidney biopsies were collected at baseline and after 2 years (n=48). Fibrosis was evaluated by quantitative stereology and classified according to Banff. Results: The groups were comparable at baseline except for slightly older allografts in the spironolactone group. Spironolactone reduced measured GFRs (up to –7.6 [95% confidence interval, −10.9 to −4.3] ml/min compared with placebo) independently of time since transplantation and BP with no effect on the kidney function curve over time and reduced 24-hour proteinuria after 1 year. There was no significant effect of spironolactone on the development of interstitial fibrosis. Conclusions: Spironolactone added to standard therapy for 3 years in kidney transplant patients did not improve kidney function, long-term proteinuria, or interstitial fibrosis. Clinical Trial registration number: NCT01602861.

29 November 2016 in Oncotarget
Verified
Journal Article
Open access
MRMaj Rabjerg
Maj Rabjerg
Barbara GuerraBarbara Guerra
Barbara Guerra
AOAida Oliván-Viguera
Aida Oliván-Viguera
MMMinne Line Nedergaard Mikkelsen
Minne Line Nedergaard Mikkelsen
RKRalf Kohler
Ralf Kohler
NMNiels Marcussen
Niels Marcussen
Nuclear localization of the CK2-subunit correlates with poor prognosis in clear cell renal cell carcinoma